Purinoceptors as therapeutic targets for lower urinary tract dysfunction. - Wikidata - wikimedia - TriplyDB

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

http://www.wikidata.org/entity/Q35545723

about

Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses Authentic role of ATP signaling in micturition reflex.In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function.Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord.Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function.Deletion of Dicer in smooth muscle affects voiding pattern and reduces detrusor contractility and neuroeffector transmission P2X2/3 and P2X3 receptors contribute to the metaboreceptor component of the exercise pressor reflex.Aging differentially modifies agonist-evoked mouse detrusor contraction and calcium signals.Role of Purinergic Signaling in Voiding Dysfunction.Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.Circadian rhythms in urinary functions: possible roles of circadian clocks?Activation and regulation of purinergic P2X receptor channels P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization.Medicinal chemistry of adenosine, P2Y and P2X receptors.Current and emerging investigational medical therapies for the treatment of overactive bladder.Cyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons.Expression and function of rat urothelial P2Y receptors.Purinergic signalling in the urinary tract in health and disease.Presence of multiple peripheral circadian oscillators in the tissues controlling voiding function in mice.Purinergic signalling in the lower urinary tract.P2X and P2Y nucleotide receptors as targets in cardiovascular disease.Painful bladder syndrome: an update and review of current management strategies.Potential Future Pharmacological Treatment of Bladder Dysfunction.Urothelial ATP signaling: what is its role in bladder sensation?2',3'-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study.AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.Novel excitatory effects of adenosine triphosphate on contractile and pacemaker activity in rabbit urethral smooth muscle.PACAP/Receptor System in Urinary Bladder Dysfunction and Pelvic Pain Following Urinary Bladder Inflammation or Stress.Cyclophosphamide-induced alterations of the micturition reflex in a novel in situ urinary bladder model in the anesthetized rat.Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace α1 -Adrenergic Tension in the Human Prostate.P2X receptor currents in smooth muscle cells contribute to nerve mediated contractions of rabbit urethral smooth muscle.Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC).Association of auricular reflective points and the status of lower urinary tract symptoms in aging males

P2860

Q26863398-041E2472-FEB0-42EF-A967-22FE4B8ABF8F Q27301269-26F81B59-BE42-4D53-9A2E-CF788D72492D Q30409620-EF4F64DA-3625-46EA-973F-D31878E38CBC Q30486732-82DD9AD4-3A7D-4F52-8B61-124CF33BCBCC Q33728157-6546E3BF-6451-454D-BFDD-9FA57FBE2E09 Q33898994-4852E1BD-F1BD-4FA8-A93C-072BF6F1B082 Q34158044-465B1C2F-8667-4009-8585-BC4019203AFC Q34256861-8A44A01D-9ADD-4BC8-827B-0954C4A3609C Q34305343-970CF11D-4F7B-4733-A390-9947798D825E Q34714783-76830BE1-C52E-484B-906F-944D5C7937D7 Q34973917-5C902D8F-0B25-4C65-8BF1-3A05890DE041 Q35057523-8335E4DE-D6F1-434A-947E-87D296167DC0 Q35112709-391D271F-4016-4A64-AEB6-903F2A55E2C3 Q35122793-B0FEBE74-DAAF-4723-8293-026818F620FA Q35464242-CF46DF23-E36B-4FBF-B82C-C70C05D67744 Q35873582-2E76C9F4-715D-4AD1-96FD-B6CF9437BF05 Q36568728-C7244568-E188-4FF4-A5B2-9C186696F474 Q37137251-F590FAFF-78A9-4320-B4E6-CFF6E0FB0C70 Q37383394-7E1962DC-6B13-4E38-BC63-3F12E248A9C0 Q37620260-26B3FF91-5268-44A4-8077-579D78FD3D9F Q37679428-E2C8F7A8-E1F1-4B78-BB03-4F27B8FECA34 Q38061933-9505F4E7-F8C3-4991-92EC-442D8B46CD14 Q38089738-120420BE-DDA1-4B07-A704-CBE0EE4A9676 Q38175328-62D5DBE7-78D7-4A21-B648-BDAFB816116D Q38779624-EDC6E929-8585-4F1A-89FB-9C5AEEC231BE Q38932041-C48A9014-F5EB-4BA1-9C5B-D806504A8B4B Q39273167-474B42DB-FA90-413C-A9CF-88CFAF425508 Q40016409-39528C8A-F3C5-4804-A185-2C43A16EFB18 Q41818439-D277941F-A8A2-4079-A975-B0651F9E2BD6 Q43215061-CBDD9047-01CA-4297-A9DE-6FB6EA518D37 Q47106917-D45712C4-D5F7-42A9-8C9A-DF7B065BAA0A Q47917716-8B9719DC-8E23-43B8-891E-3B4573DA6DFC Q47997829-0CFE951D-9953-4E0E-9451-73889270A911 Q49230231-7122FB5F-D7A9-46E2-8DC6-EFC84295AD85 Q51406371-556F5E0E-FBB2-4724-AC23-06862A5883DC Q58243977-ACDD9F5F-CE43-4707-9367-AC208D9315D2

P2860

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

http://www.wikidata.org/entity/Q35545723

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@ast

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@en

type

label

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@ast

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@en

prefLabel

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@ast

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@en

P1433

Q35545723-25A37550-6A79-4A6E-BF40-0DA4560C5BAB

P1476

Q35545723-82065858-C31D-46FB-9426-7A40AA00426B

P2093

Q35545723-0EB3684F-0380-4D89-A441-65EF3AD2A4DC

Q35545723-17354256-D931-4F16-A05C-126103B66CD7

Q35545723-5659FBF7-72DF-4D8B-A12D-FACA184CA282

Q35545723-A20428D6-05D4-451D-8E74-65EE1221E52D

Q35545723-B4F25E3B-F22E-4F85-A187-FB2D404A78DA

Q35545723-DA41B767-9FDC-4EAC-9AAA-8A1155178542

Q35545723-DE326B49-FA9D-4740-90A3-560750D13DE1

P2860

Q35545723-0461892D-F171-4AB2-86E0-F2C29FF84923

Q35545723-05FBD14E-940C-4152-86C1-14FF42DF3E45

Q35545723-0632900D-3253-4A87-B343-A18A91654D46

Q35545723-06CF352B-6F71-426A-A527-D7244A0D5255

Q35545723-0C3A36EE-7AD7-4C1C-8E8A-69CF3C7E1AF2

Q35545723-0CBCAB56-8AFA-4B34-B669-9A58D717E432

Q35545723-0DBE8B65-E377-43AC-899A-46828B1B474E

Q35545723-0F13DD9C-69DE-4B50-851C-476B92A0EADA

Q35545723-16035229-4134-4393-B467-BD1C384DC98D

Q35545723-183A8C80-5207-42EC-9789-073943CF346A

P304

Q35545723-CF1B258D-FBE1-4E98-9549-05EEB8D595FE

P31

Q35545723-C9CBA675-52F1-43D4-840C-7350DB6E305D

P356

Q35545723-D58B9BEB-32FA-4A3A-8A71-0BE36142B9D9

P407

Q35545723-4B240FF7-6049-4A14-8735-8054D81ACB8F

P478

Q35545723-9FCD4901-55BE-400C-8FF6-27C715648625

P577

Q35545723-1DEB8745-0A8D-4355-9D5D-74DB76D4B452

P5875

Q35545723-2F567E34-9DE4-49F3-96B5-B3C374DDB0E0

P698

Q35545723-302FA613-18D2-409D-8A2C-94D2A6793EEF

P932

Q35545723-03CCDA60-80FA-453E-BB79-492B36738DF1

P356

P1433

British Journal of Pharmacology

P1476

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

@en

P2093

Anthony P D W Ford

http://www.w3.org/2001/XMLSchema#string

Debra A Cockayne

http://www.w3.org/2001/XMLSchema#string

Joel R Gever

http://www.w3.org/2001/XMLSchema#string

Joseph S Cefalu

http://www.w3.org/2001/XMLSchema#string

Michael P Dillon

http://www.w3.org/2001/XMLSchema#string

Philip A Nunn

http://www.w3.org/2001/XMLSchema#string

Yu Zhong

http://www.w3.org/2001/XMLSchema#string

P2860

P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels.

PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Molecular physiology of P2X receptors

Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family

Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice

Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue

Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors

Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1

P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP

P304

S132-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0706637

http://www.w3.org/2001/XMLSchema#string

P407

P478

147 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7309559

http://www.w3.org/2001/XMLSchema#string

P698

16465177

http://www.w3.org/2001/XMLSchema#string

P932

1751490

http://www.w3.org/2001/XMLSchema#string